Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

日本批准奥密克戎新疫苗 或下周启动接种
Japan approves new Omicron vaccine or starts vaccination next week

Moomoo 24/7 ·  {{timeTz}}

日本厚生劳动省12日特例批准了针对新冠奥密克戎毒株的新疫苗的制造销售。该疫苗对目前国内流行的亚型“BA.5”也有望起效。14日召开的疫苗小组会将正式决定实施免费接种等,19日以后启动向地方政府配送的工作。从被列为第四剂疫苗接种对象的60岁以上人群及医务人员开始,启动接种工作。此次获批的是美国辉瑞公司和莫德纳公司开发的产品。

Japan's Ministry of Health and Labor approved the manufacture and sale of a new vaccine against COVID-19 Omicron strain on the 12th. The vaccine is also expected to be effective on the current domestic epidemic subtype "BA.5". The vaccine group meeting held on the 14th will formally decide to implement free vaccination and start the work of distribution to local governments after the 19th. Starting from the people over the age of 60 and medical staff who are listed as the fourth dose of vaccination, start the vaccination work. The products approved this time are products developed by Pfizer Inc and Modena in the United States.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.